Dyameo device for guiding head and neck cancer surgery
Part of Cancer clinical trials.
This trial tests a new device that helps surgeons see clear edges when removing squamous cell carcinoma (a common type of cancer) from the mouth, throat, or voice box. It is for people having standard surgery with biopsies to check for cancer cells during the operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of squamous cell carcinoma (a type of cancer) in the mouth, throat, or voice box.
- You must be scheduled for planned surgery that aims to cure this cancer and includes instant biopsy tests during the operation.
- You must be 18 years or older.
- You must be enrolled in a social security system (health insurance).
- You must not have had prior treatment with anti-EGFR antibodies (a type of targeted drug).
- Your tumor cells must have shown EGFR protein in a previous test (this protein is needed for the device to work).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether advanced imaging used during surgery can better guide where surgeons remove head-and-neck tumors. It also studies how this approach works alongside planned postoperative radiation therapy, which may be needed for more advanced tumors.
This study tests whether a virtual reality (3D computer) model of surgery can help surgeons improve how head and neck cancer operations are planned and done. You may benefit from more personalized surgical planning, if you’re eligible for standard surgery.
This early-phase study tests a new small device (placed through the skin) plus standard surgery to study head and neck cancers. It may help researchers understand how the device works and gather safety information for people who need definitive surgery for a measurable tumor.
This Phase 2 trial tests a special light-tracking medicine (cRGD-ZW800-1) to help surgeons see oral cancer during surgery. The goal is to improve how well the tumor is found and removed while keeping side effects manageable.
This trial tests a combination of two targeted drugs for advanced head and neck cancer that has not responded to standard treatments. It specifically includes patients whose tumors have a change in the CDKN2A gene.
This trial tests whether combining the drug emactinib with chemotherapy and immunotherapy before surgery helps treat advanced head and neck cancer. It aims to shrink tumors and make surgery more effective.
Hear when a new Head and Neck Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.